EASSI - Evaluation of the Safety of Self-Administration With Icatibant

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by Shire Human Genetic Therapies, Inc..
Recruitment status was  Active, not recruiting
Information provided by:
Shire Human Genetic Therapies, Inc.
ClinicalTrials.gov Identifier:
First received: October 16, 2009
Last updated: December 21, 2010
Last verified: December 2010

This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.

Condition Intervention Phase
Hereditary Angioedema
Drug: Icatibant
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema

Resource links provided by NLM:

Further study details as provided by Shire Human Genetic Therapies, Inc.:

Primary Outcome Measures:
  • Clinical safety of self-treatment of acute HAE attacks with s.c. injections of icatibant [ Time Frame: 48 hours post-dose ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Local tolerability, convenience, and clinical efficacy of self-treatment of acute HAE attacks with s.c. injections of icatibant. [ Time Frame: 48 hours post-dose ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: September 2009
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Icatibant
Single subcutaneous injection of icatibant, 30 mg
Drug: Icatibant
Single subcutaneous injection of icatibant, 30 mg


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Each patient must meet the following criteria to be enrolled in this study.

  1. Males and females 18 years of age at the time of informed consent
  2. Documented diagnosis of HAE Type I or II based on ALL of the following criteria:

    • Family and/or medical history
    • Characteristic attack manifestations, recurrent attacks
    • Historical functional C1-INH <50% normal values
  3. Women of childbearing potential must use consistently and correctly a highly effective, adequate method of birth control (failure rate less than 1% per year) - sexual abstinence or have a vasectomised partner during the duration of the study. Hormonal contraception can be continued if verified by a physician that it doesn't affect the course of HAE attacks.
  4. Mental and physical condition allowing patients to complete baseline assessment, to self-administer icatibant and to follow other study procedures.
  5. Ability to provide signed written informed consent after all aspects of the study have been explained and discussed with the patient.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

  1. Participation in a clinical trial of another investigational medicinal product within the past month (except a previous icatibant study).
  2. Diagnosis of angioedema other than Type I or Type II HAE.
  3. Evidence of symptomatic coronary artery disease based on medical history, in particular, unstable angina pectoris or severe coronary heart disease.
  4. Congestive heart failure (NYHA Class 3 and 4).
  5. Stroke within the past 6 months.
  6. Treatment with angiotensin converting enzyme (ACE) inhibitor.
  7. Pregnancy and/or breast-feeding.
  8. In the opinion of the investigator: mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study.
  9. In the opinion of the investigator: unlikely to comply with the protocol, for example, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study for any reason.
  10. In the opinion of the investigator: inability to manage study medication or self-administration of an injection.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00997204

Hospital Britanico Unidad de Alergia
Buenos Aires, Argentina, C1035AAT
Universitätsklinik für Dermatologie und Venerologie
Graz, Austria, 8036
Odense Universitetshospital-OUH
Odense, I og Alergicentret, Denmark
Centre Hospitalier Universitaire/ Service de Dermatologie
Angers, Angers Cedex 09, France, 49933
Hospital Edouaed Herriot
Lyon, Cedex 03, France, 69437
Clinique Universitaire de Medicine/ Centre National de reference
Grenoble, Grenoble Cedex 09, France, 38043
Hopital Claude Huriex/ Service de medicine interne
Lille, Lille Cedex, France, 59037
Hopital Europeen Georges Pompidou Immunologie Clinique
Paris, Paris Cedex 15, France, 75015
Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, Charité
Berlin, Germany, 10117
Universitäts-Hals-Nasen-Ohren-Klinik Essen, Universität Duisburg-Essen
Essen, Germany, 45127
Klinkum der Johann Wolfgang Goethe-Universitat
Frankfurt am Main, Germany, 60590
Hautklinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität
Mainz, Germany, 55101
Bnai-Zion M.C. Clinical Immunology and Allergy Division
Haifa, Israel, 31048
Tel Aviv Sourasky Medical Center - Allergy Unit
Tel Aviv, Israel, 64239
The Chaim Sheba Medical Center, The Allergy and Clinical Immunology Unit
Tel Hashomer, Israel, 52621
Ospedale Luigi Sacco
Milano, Italy, 20157
Universita degli Studi di Napoli 'Federico II'
Napoli,, Italy, 80131
Hospital Universitario Vall de Hebrón / Sección de Alergia, Escola Infermeria
Barcelona, Spain, 08035
Hospital General Universitario Gregorio Maranon
Madrid, Spain, 28007
Hospital Universitario La Paz, Servicio de Alergia
Madrid, Spain, 28046
Hospital Universitario La Fe, Servicio de Alergia
Valencia, Spain, 46009
Luzerner Kantonsspital
Luzern, Switzerland
Universitätsspital Zürich / Dermatologische Klinik
Zurich, Switzerland, 8091
United Kingdom
Southmead Hospital, Department of Immunology
Bristol, United Kingdom, BS10 5NB
Barts & The London NHS Trust, Pathology and Pharmacy Building
London, United Kingdom, E1 2ES
Derriford Combined Laboratory, Department of Clinical Immunology & Allergy
Plymouth, United Kingdom, PL6 8DH
Sponsors and Collaborators
Jerini AG
Study Director: Anja D. Lachmann, Dr. Jerini AG
  More Information

No publications provided

Responsible Party: Dr. Anja Lachmann, Jerini AG
ClinicalTrials.gov Identifier: NCT00997204     History of Changes
Other Study ID Numbers: JE049-3101
Study First Received: October 16, 2009
Last Updated: December 21, 2010
Health Authority: Austria: Agency for Health and Food Safety
Germany: Federal Institute for Drugs and Medical Devices
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Israel: Ethics Commission
Switzerland: Swissmedic
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Italy: Ministry of Health
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Denmark: Danish Medicines Agency

Keywords provided by Shire Human Genetic Therapies, Inc.:
Type I HAE

Additional relevant MeSH terms:
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Genetic Diseases, Inborn
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents

ClinicalTrials.gov processed this record on April 22, 2014